Recursion Pharmaceuticals, Inc. Class A Common Stock
Here’s whether Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 61 — healthy momentum range; 3-month momentum positive (+16.3%). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-1.00% over 10 days); weak 1-year return of -26.8%. Currently 51.2% off its 52-week high. Score: -1/7.
RXRX is trading below its 200-day MA ($3.70) — a key warning sign the longer-term trend is under pressure. An RSI of 60.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -26.8% compares to +20.5% for SPY (trailed the market by 47.3%). The current 51.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.